JP2019529435A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529435A5
JP2019529435A5 JP2019515307A JP2019515307A JP2019529435A5 JP 2019529435 A5 JP2019529435 A5 JP 2019529435A5 JP 2019515307 A JP2019515307 A JP 2019515307A JP 2019515307 A JP2019515307 A JP 2019515307A JP 2019529435 A5 JP2019529435 A5 JP 2019529435A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515307A
Other languages
English (en)
Japanese (ja)
Other versions
JP7487921B2 (ja
JP2019529435A (ja
Filing date
Publication date
Priority claimed from CN201610822529.0A external-priority patent/CN107235896B/zh
Application filed filed Critical
Publication of JP2019529435A publication Critical patent/JP2019529435A/ja
Publication of JP2019529435A5 publication Critical patent/JP2019529435A5/ja
Application granted granted Critical
Publication of JP7487921B2 publication Critical patent/JP7487921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515307A 2016-09-13 2017-06-22 チロシンキナーゼ阻害剤及びその応用 Active JP7487921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610822529.0 2016-09-13
CN201610822529.0A CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用
PCT/CN2017/089501 WO2018049861A1 (zh) 2016-09-13 2017-06-22 酪氨酸激酶抑制剂及其应用

Publications (3)

Publication Number Publication Date
JP2019529435A JP2019529435A (ja) 2019-10-17
JP2019529435A5 true JP2019529435A5 (cg-RX-API-DMAC10.html) 2024-03-06
JP7487921B2 JP7487921B2 (ja) 2024-05-21

Family

ID=59982910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515307A Active JP7487921B2 (ja) 2016-09-13 2017-06-22 チロシンキナーゼ阻害剤及びその応用

Country Status (8)

Country Link
US (1) US10882853B2 (cg-RX-API-DMAC10.html)
EP (1) EP3511327B1 (cg-RX-API-DMAC10.html)
JP (1) JP7487921B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190045354A (cg-RX-API-DMAC10.html)
CN (2) CN110437145A (cg-RX-API-DMAC10.html)
AU (1) AU2017325641B2 (cg-RX-API-DMAC10.html)
ES (1) ES2902549T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018049861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN112358469A (zh) * 2020-03-18 2021-02-12 北京康辰药业股份有限公司 血管生成抑制剂、其制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN105884695B (zh) * 2015-02-13 2019-02-26 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN105017163A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN105085416A (zh) * 2015-08-25 2015-11-25 佛山市赛维斯医药科技有限公司 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105001168A (zh) * 2015-08-25 2015-10-28 佛山市赛维斯医药科技有限公司 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途

Similar Documents

Publication Publication Date Title
JP2021514400A5 (cg-RX-API-DMAC10.html)
JP2021526132A5 (cg-RX-API-DMAC10.html)
JP2021523221A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2021193108A5 (cg-RX-API-DMAC10.html)
JP2021522166A5 (cg-RX-API-DMAC10.html)
JP2015515989A5 (cg-RX-API-DMAC10.html)
HRP20241768T1 (hr) Heterociklički spoj
JP2016518437A5 (cg-RX-API-DMAC10.html)
MA45020B1 (fr) Dérivés sulfonamides aromatiques
JP2013543842A5 (cg-RX-API-DMAC10.html)
CN109890820A (zh) 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
JP2017511311A5 (cg-RX-API-DMAC10.html)
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
JP2018507877A5 (cg-RX-API-DMAC10.html)
JP2016513660A5 (cg-RX-API-DMAC10.html)
ZA200401316B (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.
JP2014518544A5 (cg-RX-API-DMAC10.html)
JP2017006120A5 (cg-RX-API-DMAC10.html)
JP2017501236A5 (cg-RX-API-DMAC10.html)
JP2016501185A5 (cg-RX-API-DMAC10.html)
JP2010526098A5 (cg-RX-API-DMAC10.html)
JP2019516739A5 (cg-RX-API-DMAC10.html)
CN109952305A (zh) 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
JP2021524482A5 (cg-RX-API-DMAC10.html)